Colchicine is effective for short-term treatment of slow transit constipation: a double-blind placebo-controlled clinical trial.

PURPOSE: Although colchicine has been tested in clinical trials for treatment of constipation, the index groups in those trials were composed of special patient groups with developmental neuromuscular defects or failed surgical management. The aim of this study is to investigate the efficacy of colchicine in patients with refractory slow transit constipation. MATERIALS AND METHODS: Sixty patients with chief complaint of chronic constipation due to slow transit consented to be included in the double-blind placebo-controlled clinical trial. These patients were randomly divided into two groups (each containing 30 patients) to receive either colchicine, 1 mg QD, (group A) or placebo (group B) for 2 months. At the end of the study, Knowles-Eccersly-Scot symptom (KESS, a valid technique to assist in the diagnosis and evaluation of symptoms in constipation) scores were compared between the case and control groups. RESULTS: The mean KESS score measured at the end of 2 months was 11.67 +/- 3.91 for colchicine and 18.66 +/- 3.72 for placebo group (p = 0.0001). CONCLUSION: This trial shows that low-dose colchicine is effective in treatment of slow transit constipation.

Constipation, the sole presentation of primary renal carcinoid tumor: A case report.

Primary renal carcinoid tumors are quite rare. The pathogenesis of these tumors is unknown due to lack of enterochromaffin cells in the kidney. Because of nonspecific clinical manifestations and radiologic features, they are commonly misdiagnosed. Hence, Primary renal carcinoid tumors should be considered in differential diagnosis of any renal mass. In the present case, a 26-year-old woman was presented with a renal mass and constipation. After partial nephrectomy, diagnosis of carcinoid tumor was confirmed.

Evaluation of brushing cytology in the diagnosis of Helicobacter pylori gastritis.

OBJECTIVE: To evaluate clinical utility of rapid urease test (RUT), brash cytology and histology for detecting Helicobacter pylori. STUDY DESIGN: Brush cytology materials were obtained from the antrum of the stomach in 109 patients who suffered from dyspepsia and were candidates for endoscopy. RUT and histology with hematoxylin-eosin staining were performed. Infection status was established by observation of typical HP in cytology or biopsy. RESULTS: A total of 78% ofpatients were diagnosed as positivefor HP organisms using brush cytology; 66% had histologic results positive for HP and 59% for RUT. Observation of typical organism by cytology or histology was the gold standard; 3 tests results were compared. Sensitivity of brush cytology (95%) was higher than that of histology (80.5%) and RUT (72%). CONCLUSION: Gastric brushing cytology provides a sensitive, inexpensive, accurate and easy technique for rapid detection of HP infection. When additional information on severity of mucosal damage or presence of cell atypias is not necessary, histologic examination can be omitted; a cost-effective strategy for assessing HP status might consist of taking antral biopsies, the former for RUT, and performing brush cytology slides, which should be stained and examined only when the RUT result is negative.

Correlation of quality of life with gastroesophageal reflux disease amongst Qashqai nomads in Iran.

BACKGROUND: Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal diseases encountered in today's clinic practice. GERD symptoms are troublesome and disruptive to the physical, social and emotional well-being of many patients. This is a cross-sectional study performed on Qashqai nomads of Fars Province in southern Iran to determine the impact of GERD on quality of life. METHODS: We randomly selected 748 subjects over the age of 25 years. Subjects completed two questionnaires conducted by interviews. The first one consisted of questions on gastroesophageal reflux symptoms. The second questionnaire was the Short Form Health Survey (SF-36), a generic health-related quality of life instrument that consists of 36 items divided into eight dimensions. It has a 0- to 100-point scale where higher scores show better functioning and well-being. RESULTS: Of 748 Qashqai migrating nomads who participated in the study, 717 subjects) mean age: 43 ± 14.2 years) completed the GERD questionnaire and only 372 subjects completed the SF-36 questionnaire due to their busy lifestyles, and GERD was reported in 106 subjects (28.5%). For all dimensions of SF-36, the mean score was consistently lower in patients with GERD compared to non-GERD subjects (P < 0.001). The dimension most frequently impaired was role-physical (40.9 vs. 77.3) followed by role-emotional (44.7 vs. 77.5), physical functioning (66.9 vs. 84.6), and general health (46.8 vs. 63.8). An association existed between impairment in quality of life and frequency (P < 0.05), but not severity, of GERD symptoms.  CONCLUSION: In this group of Qashqai nomads, all dimensions of health-related quality of life as measured by the SF-36 questionnaire were meaningfully impaired in subjects with symptomatic GERD compared to non-GERD subjects. There was an association between impaired quality of life and frequency, but not severity, of GERD.

Seroprevalence of hepatitis B virus among hemodialysis patients in Bushehr province, southern Iran: HBV seroprevalence in hemodialysis patients.

BACKGROUND: Hepatitis B virus (HBV) infection is still reported from adult hemodialysis units. OBJECTIVES: To determine the prevalence of anti-HBs antibody in hemodialysis patients and the correlation between levels of anti-HBs antibody with other factors. PATIENTS AND METHODS: HBsAg, anti-HBs and anti-HBc antibodies level in 119 hemodialysis patients were evaluated by enzyme-linked immunosorbent assay. RESULTS: Seroconversion (anti-HBs antibody >10 IU/L) was found in 22 patients. Minimum protective antibody level was found in patients aged ≥60 years. Statistically significant correlation was not found between anti-HBs antibody and gender. Ten (8.4%) patients had abnormal ALT and/or AST. Prevalence of HBsAg, anti-HBc antibody, HBeAg and anti-HBe antibody were found in 8 (6.72%), 24 (25.16%), 2 (1.68%) and 3 (2.52%) patients, respectively. CONCLUSIONS: Periodic assessment of anti-HBs antibody level is strongly recommended in patients undergoing hemodialysis.